MS (70 eV, EI) m/z (%) 240 [M+, 100], 177 (20), 132 (70), 89 (10);
HRMS (70 eV) calc. for C12H13ClO3 240.0553, found 240.0505;
IR (neat): m 3055, 1717, 1603, 738 cm−1; Rf = 0.32 (hexane :
EtOAc 10 : 1).
4-[(Z)-(1-Chlorocyclohex-1-en-1-yl)carbonyl]morpholine (5e).
1H NMR (300 MHz, CDCl3): d 5.86 (d, J = 9.0 Hz, 1 H),
3.72–3.60 (m, 4 H), 3.54–3.44 (m, 4 H), 1.91–1.81 (m, 1 H),
1.71–1.60 (m, 2 H), 1.33–1.11 (m, 4 H), 1.03–0.91 (m, 4 H); 13C
NMR (75 MHz, CDCl3): d 165.1 (C), 137.8 (CH), 122.4 (C),
66.6 (CH2), 66.4 (CH2), 47.4 (CH2), 45.9 (CH2), 41.6 (CH), 32.9
(4 × CH2), 25.7 (CH2); MS (70 eV, EI) m/z (%) 257 [M+, 14],
135 (26), 86 (50), 56 (88), 41 (100); HRMS (70 eV) calc. for
C13H20ClNO2 257.1183, found 257.1139; IR (neat): m 2926, 1712,
1642, 1448 cm−1; Rf = 0.57 (hexane : EtOAc 10 : 1).
Isopropyl (Z)-2-bromo-3-cyclohexylacrylate (3j). 1H NMR
(400 MHz, CDCl3): d 7.04 (d, J = 7.8 Hz, 1 H), 5.17–5.09 (m,
1 H), 2.60–2.51 (m, 1 H), 1.75–1.66 (m, 2 H), 1.37 (d, J = 6.0 Hz,
6 H), 1.35–1.14 (m, 8 H); 13C NMR (100 MHz, CDCl3): d 162.0
(C), 149.7 (CH), 114.6 (C), 70.0 (CH), 40.9 (CH), 30.5 (2 × CH2),
25.6 (CH2), 25.1 (2 × CH2), 21.5 (CH3), 21.3 (CH3); MS (70 eV,
EI) m/z (%) 274 [M+, <1], 225 (42), 183 (100), 165 (68), 101 (27);
HRMS (70 eV) calc. for C12H19BrO2 274.0568, found 274.0659;
IR (neat): m 2929, 1726, 1450, 1264 cm−1; Rf = 0.62 (cyclohexane :
EtOAc 30 : 1).
4-[(Z)-(1-Chloro-4-methylpent-1-en-1-yl)carbonyl]morpholine
(5g). 1H NMR (400 MHz, CDCl3): d 6.07 (t, J = 7.4 Hz, 1 H),
3.72–3.53 (m, 8 H), 2.14 (apparent t, J = 7.2 Hz, 2 H), 1.78–1.68
(m, 1 H), 0.89 (d, J = 6.6 Hz, 6 H); 13C NMR (100 MHz, CDCl3,
233 K): d 165.0 (C), 132.5 (CH), 124.3 (C), 66.5 (CH2), 66.3 (CH2),
47.2 (CH), 42.1 (CH2), 36.7 (CH2), 27.6 (CH2), 22.3 (2 × CH3);
MS (70 eV, EI) m/z (%) 231 [M+, 20], 216 (32), 196 (36), 174 (86),
86 (100); HRMS (70 eV) calc. for C11H18ClNO2 231.1020, found
231.1021; IR (neat): m 2959, 1641, 1439, 1116 cm−1; Rf = 0.25
(hexane : EtOAc 3 : 1).
Ethyl (Z)-2-bromo-5-methylhex-2-enoate (3k). 1H NMR
(300 MHz, CDCl3): d 6.77 (t, J = 7.5 Hz, 1 H), 4.24 (q, J =
7.2 Hz, 2 H), 2.22–2.02 (m, 1 H), 1.87–1.72 (m, 2 H), 1.33 (t, J =
7.2 Hz, 3 H), 0.97 (d, J = 5.7 Hz, 3 H), 0.95 (d, J = 5.6 Hz, 3 H);
13C NMR (100 MHz, CDCl3): d 167.6 (C), 142.2 (CH), 134.0 (C),
60.5 (CH2), 42.5 (CH2), 28.3 (CH), 22.6 (CH3), 22.4 (CH3), 14.1
(CH3); MS (70 eV, EI) m/z (%) 205 [M+ − Et, 10], 139 (77), 118
(72), 69 (100), 55 (32); HRMS (70 eV) calc. for [C9H15BrO2 – Et]
204.9864, found 204.9888; IR (neat): m 2995, 1745, 1472 cm−1; Rf =
0.55 (cyclohexane : EtOAc 30 : 1).
(Z)-2-Chloro-N,N-diethyl-4-methylhex-2-enamide (5h). 1H
NMR (300 MHz, CDCl3): d 5.73 (d, J = 9.4 Hz, 1 H), 3.41 (q, J =
7.1 Hz, 4 H), 2.71–2.61 (m, 1 H), 1.48–1.39 (m, 2 H), 1.19 (t, J =
7.1 Hz, 6 H), 1.05 (d, J = 6.7 Hz, 3 H), 0.93 (t, J = 7.4 Hz, 3 H);
13C NMR (100 MHz, CDCl3, 233 K): d 164.1 (C), 136.0 (CH),
123.8 (C), 42.9 (CH2), 39.1 (CH2), 34.6 (CH), 29.1 (CH2), 19.2
(CH3), 14.0 (CH3), 12.4 (CH3), 11.9 (CH3); MS (70 eV, EI) m/z
(%) 217 [M+, 50], 182 (99), 160 (100), 145 (68); HRMS (70 eV)
calc. for C11H20ClNO 217.1233, found 217.1222; IR (neat): m
3511, 2949, 1643, 1458 cm−1; Rf = 0.41 (hexane : EtOAc 3 : 1).
Ethyl
(Z)-2-fluorocyclohexyl-2-enoate
(3l). 1H
NMR
(400 MHz, CDCl3): d 6.01 (dd, J = 34.2, 9.6 Hz, 1 H),
4.43 (q, J = 6.8 Hz, 2 H), 2.61–2.53 (m, 1 H), 1.94–1.84 (m, 2 H),
1.74–1.63 (m, 4 H), 1.41 (t, J = 6.8 Hz, 3 H), 1.34–1.11 (m, 4 H);
13C NMR (100 MHz, CDCl3): d 161.9 (C), 146.5 (d, J = 253.5 Hz,
C), 125.5 (d, J = 11.7 Hz, CH), 64.7 (CH2), 33.9 (CH), 31.9 (2 ×
CH2), 25.7 (CH2), 25.3 (2 × CH2), 13.6 (CH3); MS (70 eV, EI)
m/z (%) 200 [M+, 28], 81 (100), 67 (83), 55 (59); HRMS (70 eV)
calc. for C11H17FO2 200.1213, found 200.1223; IR (neat): m 1729,
1265, 740 cm−1; Rf = 0.20 (hexane : EtOAc 20 : 1).
(Z)-2-Chloro-N,N-diethyldec-2-enamide (5a). 1H NMR
(400 MHz, CDCl3): d 5.96 (t, J = 7.1 Hz, 1 H), 3.41–3.33 (m,
4 H), 2.24 (apparent q, J = 7.2 Hz, 2 H), 1.41–1.39 (m, 2 H),
1.25–1.15 (m, 8 H), 1.19 (t, J = 7.1 Hz, 3 H), 1.15 (t, J = 7.1 Hz,
3 H), 0.85 (t, J = 6.9 Hz, 3 H); 13C NMR (100 MHz, CDCl3,
233 K): d 165.8 (C), 131.0 (CH), 124.3 (C), 42.8 (CH2), 38.8
(CH2), 31.7 (2 × CH2), 29.1 (CH2), 27.8 (CH2), 22.6 (2 × CH2),
14.2 (CH3), 13.9 (CH3), 12.3 (CH3); MS (70 eV, EI) m/z (%) 259
[M+, 15], 224 (100), 187 (32), 160 (79); HRMS (70 eV) calc. for
C14H26ClNO 259.1703, found 259.1727; IR (neat): m 3451, 2974,
1642, 1460 cm−1; Rf = 0.52 (hexane : EtOAc 3 : 1).
(Z)-2-Chloro-N,N-diisopropyldec-2-enamide (5b). 1H NMR
(400 MHz, CDCl3, 233 K): d 5.81 (t, J = 7.2 Hz, 1 H), 4.02–
3.95 (m, 1 H), 3.80–3.40 (m, 1 H), 2.11 (apparent q, J = 6.8 Hz,
2 H), 1.40–1.09 (m, 10 H), 1.30 (d, J = 5.8 Hz, 6 H), 1.17 (d, J =
6.0 Hz, 6 H), 0.81 (m, 3 H); 13C NMR (100 MHz, CDCl3, 233
K): d 165.4 (C), 129.3 (CH), 126.7 (C), 48.0 (CH), 44.2 (CH), 31.6
(CH2), 29.5 (CH2), 29.0 (CH2), 28.8 (CH2), 22.5 (CH2), 20.5 (2 ×
CH3), 20.2 (CH2), 20.0 (2 × CH3), 13.9 (CH3); MS (70 eV, EI)
m/z (%) 287 [M+, 8], 252 (100), 201 (41); HRMS (70 eV) calc. for
C16H30ClNO 287.2016, found 287.2025; IR (neat): m 3444, 2927,
1643, 1431 cm−1; Rf = 0.55 (hexane : EtOAc 10 : 1).
(Z)-2-Chloro-N,N-diethyltrideca-2,12-dienamide
(5i). 1H
NMR (400 MHz, CDCl3): d 5.94 (t, J = 7.1 Hz, 1 H), 5.84–5.75
(m, 1 H), 5.01–4.89 (m, 2 H), 3.42–3.30 (m, 4 H), 2.25–2.20 (m,
2 H), 2.04–1.96 (m, 2 H), 1.42–1.10 (m, 12 H), 1.17 (t, J = 6.9 Hz,
3 H), 1.13 (t, J = 7.0 Hz, 3 H); 13C NMR (100 MHz, CDCl3, 233
K): d 166.2 (C), 139.8 (CH), 131.3 (CH), 124.7 (C), 114.4 (CH2),
43.2 (CH2), 39.2 (CH2), 34.2 (CH2), 29.8 (CH2), 29.7 (CH2), 29.5
(CH2), 29.4 (CH2), 29.0 (CH2), 28.3 (2 × CH2), 14.3 (CH3), 12.7
(CH3); MS (70 eV, EI) m/z (%) 299 [M+, 6], 264 (100), 160 (94),
41 (72); HRMS (70 eV) calc. for C17H30ClNO 299.2016, found
299.2022; IR (neat): m 3440, 2927, 1659, 1462 cm−1; Rf = 0.42
(hexane : EtOAc 3 : 1).
(Z)-2-Chloro-N,N-diethyl-4-phenylpent-2-enamide
(5j). 1H
NMR (400 MHz, CDCl3, 233 K): d 7.42–7.10 (m, 5 H), 5.94
(d, J = 9.2 Hz, 1 H), 3.93–3.84 (m, 1 H), 3.28–3.19 (m, 2 H),
3.15–3.06 (m, 2 H), 1.29 (d, J = 6.8 Hz, 3 H), 0.98 (t, J = 6.8 Hz,
3 H), 0.96 (t, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3, 233
K): d 165.2 (C), 143.1 (C), 134.4 (CH), 128.4 (2 × CH), 127.2 (C),
126.5 (2 × CH), 123.0 (CH), 42.7 (CH), 38.9 (CH2), 38.0 (CH2),
20.2 (CH3), 13.6 (CH3), 12.1 (CH3); MS (70 eV, EI) m/z (%) 265
[M+, 47], 230 (100), 158 (98), 129 (89), 72 (71); HRMS (70 eV)
calc. for C15H20ClNO 265.1233, found 265.1191; IR (neat): m
3425, 1615, 1451, 701cm−1; Rf = 0.35 (hexane : EtOAc 3 : 1).
General procedure for the synthesis of a-halo-a,b-unsaturated
ketones 9. The requisite organolithium compound (3.0 mmol)
was added dropwise to the corresponding morpholine amide 3
2938 | Org. Biomol. Chem., 2008, 6, 2934–2940
This journal is
The Royal Society of Chemistry 2008
©